AbbVie Beats Antitrust Challenge To Humira 'Patent Thicket'
By Lauraann Wood · June 8, 2020, 7:02 PM EDT
Humira buyers have alleged neither an antitrust violation nor an antitrust injury in their novel lawsuit claiming AbbVie built a "patent thicket" around its immunosuppressant drug Humira to block cheaper biosimilars...
To view the full article, register now.